Pharma Services Overview
The rapid advancement of related technologies and dramatic decrease in cost has led next-generation sequencing (NGS) to become a powerful tool for the research and development of medicines by the pharmaceutical industry. From the study of biological mechanisms to the search for predictive biomarkers to the screening of target patients for clinical trials, NGS is increasingly employed in applications of precision medicine. Furthermore, the recent FDA approvals of MSK-IMPACT and F1CDx represent a historical step forward in the application of NGS in clinical diagnosis. Some new treatment modalities (e.g. personalized cancer vaccine) may have even higher demand for NGS.
As the world’s largest NGS service provider, Novogene recognizes this trend and now offers our pharma clients several key clinical-grade assays (see the list below) in our CAP-certified lab in China and our US lab, which will be CLIA-certified in Q1 2018. Additional assays will be added to the list as they are developed and validated. We are fully committed to helping you meet your drug R&D goals with our unparalleled scale, efficiency, quality, and price.
Clinical Services Overview
In addition to applying our expertise to assist in NGS-based research, Novogene has developed a set of clinical tests, with more under development. These tests are currently performed for patient diagnosis in our CAP-certified lab in China. Over time, as we gain certification and approval in other countries, the tests will be available for enhancing personalized medicine around the world. For the time being, the NovoPM™ test is available now for RUO globally. The development and content of these tests are a result of collaborations that Novogene has undertaken with premier medical institutions and clinical experts around the world. The NovoPM panel has been validated on >14,000 patient samples, establishing the validity and effectiveness of the panels for content and performance. Thus, these tests can be used with full confidence in their efficacy.